Life sciences briefing: Thursday, Nov. 15, 2007

Featured companies: BioVex, FullTurn Media, Humanetics, N Spine, Novitas Capital, Reliant Technologies, Symbios, Vaxart, Virtual Radiologic, Winston Laboratories, Zosano Pharma

BioVex raises $22M for cancer-killing viruses

Woburn, Mass.-based BioVex, a biotech working on new ways to attack cancer and infections, raised $22 million in a fifth funding round. Triathlon Medical Ventures led the round, joined by New Science Ventures, Forbion Capital Ventures, Avalon Ventures, Credit Agricole Private Equity, GeneChem Management, Innoven Partners and Scottish Equity Partners.

Profectus Bio pulls in $3M for antiviral drugs

Profectus BioSciences, a Baltimore, Md., developer of antiviral drugs and vaccines targeting HIV, raised $3 million in a private placement. Private investors, including Cross Atlantic Capital Partners and board member Stewart Greenebaum, contributed.